Cargando…
Radiotherapy for Clinically Localized T3b or T4 Very-High-Risk Prostate Cancer-Role of Dose Escalation Using High-Dose-Rate Brachytherapy Boost or High Dose Intensity Modulated Radiotherapy
SIMPLE SUMMARY: Recently, high-risk prostate cancer was subdivided to a very-high-risk group considered to have the worst prognosis, including clinical stage T3b–T4, primary Gleason pattern 5, or more than four biopsy cores with Gleason score 8–10. Among these, T3b–T4 stage is a special interest in...
Autores principales: | Yamazaki, Hideya, Suzuki, Gen, Masui, Koji, Aibe, Norihiro, Shimizu, Daisuke, Kimoto, Takuya, Yoshida, Ken, Nakamura, Satoaki, Okabe, Haruumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8070084/ https://www.ncbi.nlm.nih.gov/pubmed/33924563 http://dx.doi.org/10.3390/cancers13081856 |
Ejemplares similares
-
Conventional dose versus dose escalated radiotherapy including high-dose-rate brachytherapy boost for patients with Gleason score 9–10 clinical localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2022) -
High-dose-rate brachytherapy with external beam radiotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer
por: Yamazaki, Hideya, et al.
Publicado: (2021) -
Ultrahypofractionated Radiotherapy versus Conventional to Moderate Hypofractionated Radiotherapy for Clinically Localized Prostate Cancer
por: Yamazaki, Hideya, et al.
Publicado: (2021) -
Role of Brachytherapy Boost in Clinically Localized Intermediate and High-Risk Prostate Cancer: Lack of Benefit in Patients with Very High-Risk Factors T3b–4 and/or Gleason 9–10
por: Yamazaki, Hideya, et al.
Publicado: (2022) -
High-Dose-Rate Brachytherapy Monotherapy versus Image-Guided Intensity-Modulated Radiotherapy with Helical Tomotherapy for Patients with Localized Prostate Cancer
por: Yamazaki, Hideya, et al.
Publicado: (2018)